Click any tag below to further narrow down your results
Links
Apple has launched a 12-month study app that asks 200,000 US adults aged 21 and up to use a health chatbot built on OpenEvidence, which answers from peer-reviewed sources like NEJM and JAMA. The study is measuring whether people understand, trust, and find useful the answers health AI gives them.
- Participants need an iPhone 15 Pro or later running iOS 26, and can optionally share HealthKit data such as sleep, labs, and heart rate for more personal answers.
- Questions are stripped of identifying details on the phone, routed through a third-party contractor, then sent to OpenEvidence, which deletes question and response data within 24 hours.
- Study data won't be used to train AI models, though it may shape Apple's own health feature development. There's no live monitoring, and self-harm questions trigger only an automated suggestion to seek help.
This is the second part of an investigation into whether OpenEvidence, a medical AI company valued at $15B, has technology and content worth that price. The author finds the proprietary AI, content ownership, and accuracy claims all look weak under scrutiny.
- OpenEvidence doesn't own its content; publishers can pull their material at any time, which undercuts the moat a buyer would be paying for.
- Accuracy claims collapse outside exam settings: the company's near-perfect USMLE scores drop to about 27% on real-world clinical cases.
- Ad revenue projections ($400M to $500M in 2026) still put the $15B valuation at 30x to 37.5x a single year of sales, and the company's own CEO now pitches drug discovery as the real prize.
A journalist investigates OpenEvidence's $15B valuation after the company signaled openness to acquisition, arguing the "ChatGPT for doctors" startup is worth roughly one-third that amount based on comparable healthtech deals and its claimed $300M ARR.
- OpenEvidence claims $300M in annual recurring revenue but comparable healthtech acquisitions suggest a $500M valuation maximum; founder Daniel Nadler is seeking 30x that amount, relying on his Goldman Sachs network and investor clout to pull it off.
- Livongo's acquisition by Teladoc for $18.5B followed by a $340M writedown serves as a cautionary tale for OpenEvidence's valuation, showing how healthtech M&A can collapse post-acquisition when growth claims don't materialize.
- The author's Part 2 investigation will examine OpenEvidence's actual technology, its lack of proprietary content (publishers can pull it anytime), and accuracy issues ranging from 100% on standardized tests to 27% on real-world medical cases.
OpenEvidence, an AI clinical search tool used by 40% of US physicians, raised $250 million at a $15 billion valuation — a 25% jump from January — and is now considering acquisition offers instead of going public. The company's hitting roughly $300 million in annual revenue.
- OpenEvidence closed a $250M funding round at $15B valuation, doubling its January $12B mark in nine months
- The company commands 40% of the US physician market and generated ~$300M annualized revenue by mid-2026
- Founders are actively exploring acquisition interest rather than pursuing an IPO path
Anthropic has partnered with OpenEvidence, a medical AI company, to take its health-focused AI tools global. The deal follows Anthropic's recent build-out of a physical biology lab as it pushes into drug science.
- Anthropic and OpenEvidence are partnering to expand medical AI tools to markets worldwide.
- The move comes days after Reuters reported Anthropic had set up a lab for hands-on biology work tied to its drug science push.
- The article notes rising public and political unease about AI's reach, with some executives and lawmakers calling for a slowdown in development.
OpenEvidence is an AI search tool for doctors that indexes only peer-reviewed journals and clinical guidelines. Clinicians verify their credentials to access aggregated, real-time research from sources like JAMA and NEJM, cutting down on AI hallucinations. The free, ad-supported platform has just closed a $200 million Series C round at a $6 billion valuation.
- OpenEvidence raised $200M just three months after its $210M Series B, hitting a $6B valuation
- It's a credential-gated AI search tool for doctors that only pulls from peer-reviewed sources like JAMA, NEJM, PubMed, CDC and FDA to avoid hallucinations
- It's explicitly not for patients—designed to help doctors stay current on unfamiliar diseases, treatments, or new protocols
- The platform is free and ad-supported